MB-110

Hepatitis C

superior inhibition capacity against prevalent HCV genotypes in Asia (1b, 2a and 3a)

Obtained the investigational new drug (IND) approval from FDA for human clinical trial

Small molecule, highly active and selective inhibitor of NS5A protein of hepatitis C virus (HCV)

According to the statistics of the World Health Organization, about 700,000 people die of liver diseases related to hepatitis C every year. By 2015, the global market has reached 24 billion U.S. dollars. According to the IMS data, the global anti-hepatitis C drug will reach 36 billion U.S. dollars by 2020